Mitsubishi Corporation Energy facilitated the trial for Tohoku Electric Power by supplying biofuel in the Keihin area.

Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 ...

First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable ...

Study Progresses to Fourth Higher 90 mg/m2Dose CohortCompelling Patient Response Highlighted by Stable Disease and Significant Reduction in Blast ...

An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...

HOUSTON - Bio-Path Holdings, Inc. (NASDAQ:BPTH), a biotechnology company with a market capitalization of $3.1 million, has announced continued progress in its clinical trials for cancer treatments.

A University of Nebraska-Lincoln research team has identified new microscopic players in the global carbon cycle, a discovery ...

Archer-Daniels-Midland offers value with a 4.4% dividend yield, growth initiatives, and cost-cutting strategies. See why we ...

Accord BioPharma Inc., the U.S. specialty division of Intas Pharmaceuticals Ltd., has reached an exclusive commercialization and license agreement with Bio-Thera Solutions for BAT2506, a biosimilar ...

Boca Raton, Florida Wednesday, February 12, 2025, 16:00 Hrs [IST] ...

Rebranding Invizyne Technologies, Inc to Changing NASDAQ ticker from IZTC to EXOZIntroducing but not trademarking “exozymes” ...